Zenas BioPharma (ZBIO) director receives grant of 18,500 stock options at $18.71

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Zenas BioPharma, Inc. director Hongbo Lu received a grant of stock options covering 18,500 shares of common stock. The options have an exercise price of $18.71 per share, expire on June 15, 2036, and will vest 100% on June 15, 2027, subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lu Hongbo

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 18,500 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 18,500 options Exercise price: $18.71 per share Expiration date: June 15, 2036 +1 more

4 metrics

Options granted 18,500 options Grant of stock options to director Hongbo Lu

Exercise price $18.71 per share Strike price of stock option award

Expiration date June 15, 2036 Option term end date

Vesting date June 15, 2027 100% of underlying shares vest on this date

Key Terms

Stock Option (Right to Buy), exercise price, vesting commencement date, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 18.7100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting commencement date financial

"the first anniversary of the vesting commencement date, subject to continued service"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

expiration date financial

"expiration_date: 2036-06-15T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/17/2026 - 06:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lu Hongbo

(Last)

(First)

(Middle)

C/O ZENAS BIOPHARMA, INC.

852 WINTER ST., SUITE 250

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zenas BioPharma, Inc. [ ZBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$18.71	06/15/2026		A		18,500		⁽¹⁾	06/15/2036	Common Stock	18,500	$0	18,500	D

Explanation of Responses:

1. The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.

	By: /s/ Jeffrey Held, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Zenas BioPharma (ZBIO) report for Hongbo Lu?

Zenas BioPharma reported that director Hongbo Lu received a grant of stock options. The award covers 18,500 shares of common stock and is part of his compensation, rather than an open-market purchase or sale of existing shares.

How many Zenas BioPharma (ZBIO) options were granted to Hongbo Lu?

Hongbo Lu was granted stock options on 18,500 underlying shares of Zenas BioPharma common stock. This award increases his potential future equity exposure if the options vest and are exercised at or above the stated exercise price.

What is the exercise price of Hongbo Lu’s Zenas BioPharma (ZBIO) stock options?

The stock options granted to Hongbo Lu carry an exercise price of $18.71 per share. This is the price he would pay per share to convert the options into common stock after vesting, if he chooses to exercise them.

When do Hongbo Lu’s Zenas BioPharma (ZBIO) stock options vest?

The options granted to Hongbo Lu vest as to 100% of the underlying shares on June 15, 2027. Vesting is conditioned on his continued service with Zenas BioPharma through that first anniversary vesting date.

When do Hongbo Lu’s Zenas BioPharma (ZBIO) stock options expire?

The options granted to Hongbo Lu expire on June 15, 2036. After this expiration date, any unexercised portion of the 18,500-share option award will lapse and can no longer be converted into Zenas BioPharma common stock.

Did Zenas BioPharma (ZBIO) report any open-market insider buying or selling?

No open-market buying or selling was reported in this filing. The Form 4 only shows a compensation-related grant of stock options to director Hongbo Lu, not a purchase or sale of already outstanding Zenas BioPharma shares.